Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24904309 | 0.86 | FTO (0.56) | PTPN1MAOAMAOBFTOACHE | |
| SCHEMBL11557718 | 0.83 | MAOB (0.44) | MAOAMAOBFTOACHEDYRK1A | |
| SCHEMBL127099 | 0.81 | PTPN1 (0.43) | PTPN1MAOAMAOBFTOACHE | |
| SCHEMBL13310593 | 0.76 | TNKS (0.50) | PTPN1MAOBKDM4ETBK1 | |
| SCHEMBL932337 | 0.76 | MAOA (0.59) | MAOAMAOBFTOACHEDYRK1A | |
| SCHEMBL23334899 | 0.75 | TNKS (0.49) | PTPN1ACHEKDM4ETBK1 | |
| Ethane SCHEMBL27840767 | 0.74 | MAOA (0.55) | PTPN1MAOAMAOBFTOACHE | |
| SCHEMBL12386894 | 0.73 | FTO (0.50) | MAOAMAOBFTOKDM4ESIGMAR1 | |
| SCHEMBL365385 | 0.73 | MAOA (0.58) | PTPN1MAOAMAOBFTOACHE | |
| SCHEMBL2607415 | 0.73 | HTR1B (0.49) | PTPN1DYRK1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106316999-B | A kind of preparation method and application of two ketoximes derivatives of benzofuran -2,3- | 江苏强盛功能化学股份有限公司 | 2019-01-08 | — | — | CN | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | PTPN1 1597/4885MAOA 1717/4885MAOB 2855/4885 |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | PTPN1 3983/4885MAOA 804/4885MAOB 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.